{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:46Z","timestamp":1793924506766,"version":"4.8.0"},"reference-count":85,"publisher":"Bentham Science Publishers Ltd.","issue":"20","funder":[{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2018R01015"],"award-info":[{"award-number":["2018R01015"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LY19B020008"],"award-info":[{"award-number":["LY19B020008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New-shoot Talents Program of Zhejiang Province","award":["2022R403081"],"award-info":[{"award-number":["2022R403081"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The sartans are a new class of antihypertensive drugs as angiotensin II receptor\nblockers which possess plenty of advantages in treating hypertension and related\npathologies. This review describes the clinical treatment, side effects, and potential therapeutic\neffects of sartans from 1995 to date. The synthesis, structural-activity and molecular\ndocking with Angiotensin Type 1 receptor of imidazole derivatives, benzimidazole\nderivatives and other compounds are also described. With a clear Structure-Activity Relationship\nand abundant pharmacological effects, some types of novel Angiotensin Type 1\nreceptor antagonists are emerging gradually for further research in the meantime.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220829101436","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:38:57Z","timestamp":1661845137000},"page":"2247-2266","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Research Progress in Pharmacological Mechanisms, Structure-Activity\nRelationship and Synthesis of Sartans"],"prefix":"10.2174","volume":"30","author":[{"given":"Ye-Fan","family":"Wang","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Ren","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/cmdc.201200109","volume":"7","author":"Rao G.W.","year":"2012","unstructured":"Rao G.W.; Guo Y.M.; Hu W.X.; Synthesis, structure analysis, and antitumor evaluation of 3,6-dimethyl-1,2,4,5-tetrazine-1,4-dicarboxamide derivatives. ChemMedChem 2012,7(6),973-976","journal-title":"ChemMedChem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1016\/j.bmcl.2013.09.036","volume":"23","author":"Rao G.W.","year":"2013","unstructured":"Rao G.W.; Wang C.; Wang J.; Zhao Z.G.; Hu W.X.; Synthesis, structure analysis, antitumor evaluation and 3D-QSAR studies of 3,6-disubstituted-dihydro-1,2,4,5-tetrazine derivatives. Bioorg Med Chem Lett 2013,23(23),6474-6480","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cmdc.201300120","volume":"8","author":"Rao G.W.","year":"2013","unstructured":"Rao G.W.; Xu G.J.; Wang J.; Jiang X.L.; Li H.B.; Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. ChemMedChem 2013,8(6),928-933","journal-title":"ChemMedChem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/hc-2017-0066","volume":"24","author":"Jin H.","year":"2018","unstructured":"Jin H.; Dan H.G.; Rao G.W.; Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors. Heterocycl Commun 2018,24(1),1-10","journal-title":"Heterocycl Commun"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2174\/1570193X15666181029130418","volume":"16","author":"Wu Y.C.","year":"2019","unstructured":"Wu Y.C.; Ren X.Y.; Rao G.W.; Research progress of diphenyl urea derivatives as anticancer agents and synthetic methodologies. Mini Rev Org Chem 2019,16(7),617-630","journal-title":"Mini Rev Org Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00044-009-9182-z","volume":"19","author":"Jain A.","year":"2010","unstructured":"Jain A.; Chaturvedi S.C.; QSAR modeling of some substituted benzimidazole as angotensin II AT1 receptor antagonist. Med Chem Res 2010,19(2),177-185","journal-title":"Med Chem Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.bmc.2006.02.044","volume":"14","author":"Mavromoustakos T.","year":"2006","unstructured":"Mavromoustakos T.; Moutevelis-Minakakis P.; Kokotos C.G.; Kontogianni P.; Politi A.; Zoumpoulakis P.; Findlay J.; Cox A.; Balmforth A.; Zoga A.; Iliodromitis E.; Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues. Bioorg Med Chem 2006,14(13),4353-4360","journal-title":"Bioorg Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejphar.2012.08.003","volume":"695","author":"Jani N.V.","year":"2012","unstructured":"Jani N.V.; Ziogas J.; Angus J.A.; Schiesser C.H.; Macdougall P.E.; Grange R.L.; Wright C.E.; Dual action molecules: Bioassays of combined novel antioxidants and angiotensin II receptor antagonists. Eur J Pharmacol 2012,695(1-3),96-103","journal-title":"Eur J Pharmacol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jmgm.2017.08.004","volume":"77","author":"Aksoydan B.","year":"2017","unstructured":"Aksoydan B.; Kantarcioglu I.; Erol I.; Salmas R.E.; Durdagi S.; Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives. J Mol Graph Model 2017,77,240-249","journal-title":"J Mol Graph Model"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2174\/1568026043451302","volume":"4","author":"Mavromoustakos T.","year":"2004","unstructured":"Mavromoustakos T.; Zervou M.; Zoumpoulakis P.; Kyrikou I.; Benetis N.; Polevaya L.; Roumelioti P.; Giatas N.; Zoga A.; Minakakis P.; Kolocouris A.; Vlahakos D.; Grdadolnik S.G.; Matsoukas J.; Conformation and bioactivity. Design and discovery of novel antihypertensive drugs. Curr Top Med Chem 2004,4(4),385-401","journal-title":"Curr Top Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3987\/COM-07-11309","volume":"75","author":"Rapposelli S.","year":"2008","unstructured":"Rapposelli S.; Cuboni S.; Digiacomo M.; Lucacchini A.; Minutolo F.; Letizia Trincavelli M.; Balsamo A.; Synthesis and affinity evaluation for AT1 receptor of phenylsalicylaldoximederivatives structurally related to sartans. Heterocycles 2008,75(6),1467-1477","journal-title":"Heterocycles"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1021\/jm0600186","volume":"49","author":"Breschi M.C.","year":"2006","unstructured":"Breschi M.C.; Calderone V.; Digiacomo M.; Macchia M.; Martelli A.; Martinotti E.; Minutolo F.; Rapposelli S.; Rossello A.; Testai L.; Balsamo A.; New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties. J Med Chem 2006,49(8),2628-2639","journal-title":"J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/jcbfm.2009.82","volume":"29","author":"Takizawa S.","year":"2009","unstructured":"Takizawa S.; Dan T.; Uesugi T.; Nagata E.; Takagi S.; van Ypersele de Strihou C.; Miyata T.; A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage. J Cereb Blood Flow Metab 2009,29(10),1665-1672","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/ATVBAHA.108.172841","volume":"28","author":"Izuhara Y.","year":"2008","unstructured":"Izuhara Y.; Sada T.; Yanagisawa H.; Koike H.; Ohtomo S.; Dan T.; Ito S.; Nangaku M.; van Ypersele de Strihou C.; Miyata T.; A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008,28(10),1767-1773","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.csbj.2022.04.010","volume":"20","author":"Ridgway H.","year":"2022","unstructured":"Ridgway H.; Moore G.J.; Mavromoustakos T.; Tsiodras S.; Ligielli I.; Kelaidonis K.; Chasapis C.T.; Gadanec L.K.; Zulli A.; Apostolopoulos V.; Petty R.; Karakasiliotis I.; Gorgoulis V.G.; Matsoukas J.M.; Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Comput Struct Biotechnol J 2022,20,2091-2111","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejmech.2012.01.043","volume":"50","author":"Garc\u00eda G.","year":"2012","unstructured":"Garc\u00eda G.; Serrano I.; S\u00e1nchez-Alonso P.; Rodr\u00edguez-Puyol M.; Alajar\u00edn R.; Griera M.; Vaquero J.J.; Rodr\u00edguez-Puyol D.; \u00c1lvarez-Builla J.; D\u00edez-Marqu\u00e9s M.L.; New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers. Eur J Med Chem 2012,50,90-101","journal-title":"Eur J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00775-016-1384-5","volume":"21","author":"Islas M.S.","year":"2016","unstructured":"Islas M.S.; Luengo A.; Franca C.A.; Merino M.G.; Calleros L.; Rodriguez-Puyol M.; Lezama L.; Ferrer E.G.; Williams P.A.M.; Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)\u2013irbesartan complex: Structure\u2013antihypertensive activity relationships in Cu(II)\u2013sartan complexes. J Biol Inorg Chem 2016,21(7),851-863","journal-title":"J Biol Inorg Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/235709","volume":"2015","author":"Jani\u0107 M.","year":"2015","unstructured":"Jani\u0107 M.; Lunder M.; \u0160abovi\u010d M.; A low-dose combination of fluvastatin and valsartan: a new \u201cdrug\u201d and a new approach for decreasing the arterial age. BioMed Res Int 2015,2015,1-6","journal-title":"BioMed Res Int"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.freeradbiomed.2020.08.007","volume":"160","author":"Tsiailanis A.D.","year":"2020","unstructured":"Tsiailanis A.D.; Renziehausen A.; Kiriakidi S.; Vrettos E.I.; Markopoulos G.S.; Sayyad N.; Hirmiz B.; Aguilar M.I.; Del Borgo M.P.; Kolettas E.; Widdop R.E.; Mavromoustakos T.; Crook T.; Syed N.; Tzakos A.G.; Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. Free Radic Biol Med 2020,160,391-402","journal-title":"Free Radic Biol Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.04.002","volume":"135","author":"Regoli D.","year":"2012","unstructured":"Regoli D.; Plante G.E.; Gobeil F.; Impact of kinins in the treatment of cardiovascular diseases. Pharmacol Ther 2012,135(1),94-111","journal-title":"Pharmacol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1164\/rccm.201208-1480ED","volume":"186","author":"Ranayhossaini D.","year":"2012","unstructured":"Ranayhossaini D.; Pagano P.J.; TrACEing angiotensin II type 1 to right ventricular hypertrophy: Are the \u201csartans\u201d a viable course to treating pulmonary arterial hypertension? Am J Respir Crit Care Med 2012,186(8),705-707","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1517\/14656566.9.8.1397","volume":"9","author":"Inoue T.","year":"2008","unstructured":"Inoue T.; Node K.; Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008,9(8),1397-1406","journal-title":"Expert Opin Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2133.2002.48848.x","volume":"147","author":"Marquart-Elbaz C.","year":"2002","unstructured":"Marquart-Elbaz C.; Grosshans E.; Alt M.; Lipsker D.; Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002,147(3),617-618","journal-title":"Br J Dermatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nephro.2007.03.003","volume":"3","author":"Roskiewicz F.","year":"2007","unstructured":"Roskiewicz F.; Andriamanana I.; Gras-Champel V.; Andrejak M.; Massy Z.A.; Iatrogenic angioedema: The role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers. Nephrol Ther 2007,3(3),89-95","journal-title":"Nephrol Ther"},{"key":"ref=25","first-page":"73","volume":"20","author":"Tsepkentzi E.","year":"2016","unstructured":"Tsepkentzi E.; Sarafidis K.; Sotiriadis A.; Chatzistamatiou K.; Drossou-Agakidou V.; Neonatal acute kidney injury following Valsartan exposure in utero: Report of two cases. Hippokratia 2016,20(1),73-75","journal-title":"Hippokratia"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bdra.20102","volume":"73","author":"Alwan S.","year":"2005","unstructured":"Alwan S.; Polifka J.E.; Friedman J.M.; Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005,73(2),123-130","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/bjp.2008.218","volume":"154","author":"M\u0105czewski M.","year":"2008","unstructured":"M\u0105czewski M.; M\u0105czewska J.; Duda M.; Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: Role of angiotensin II type 1 receptors. Br J Pharmacol 2008,154(8),1640-1648","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.02.019","volume":"23","author":"Sato K.","year":"2014","unstructured":"Sato K.; Yamashita T.; Kurata T.; Fukui Y.; Hishikawa N.; Deguchi K.; Abe K.; Telmisartan ameliorates inflammatory responses in SHR-SR after tMCAO. J Stroke Cerebrovasc Dis 2014,23(10),2511-2519","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.09.037","volume":"24","author":"Kono S.","year":"2015","unstructured":"Kono S.; Kurata T.; Sato K.; Omote Y.; Hishikawa N.; Yamashita T.; Deguchi K.; Abe K.; Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke. J Stroke Cerebrovasc Dis 2015,24(3),537-547","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ajh\/hpu197","volume":"28","author":"Villapol S.","year":"2015","unstructured":"Villapol S.; Saavedra J.M.; Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015,28(3),289-299","journal-title":"Am J Hypertens"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awv172","volume":"138","author":"Villapol S.","year":"2015","unstructured":"Villapol S.; Balarezo M.G.; Affram K.; Saavedra J.M.; Symes A.J.; Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain 2015,138(11),3299-3315","journal-title":"Brain"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/0929867323666151117122116","volume":"23","author":"Kellici T.","year":"2015","unstructured":"Kellici T.; Ntountaniotis D.; Kritsi E.; Zervou M.; Zoumpoulakis P.; Potamitis C.; Durdagi S.; Salmas R.; Ergun G.; Gokdemir E.; Halabalaki M.; Gerothanassis I.; Liapakis G.; Tzakos A.; Mavromoustakos T.; Leveraging NMR and X-ray data of the free ligands to build better drugs targeting angiotensin II type 1 G-protein coupled receptor. Curr Med Chem 2015,23(1),36-59","journal-title":"Curr Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/molecules25061375","volume":"25","author":"Lin X.","year":"2020","unstructured":"Lin X.; Li X.; Lin X.; A review on applications of computational methods in drug screening and design. Molecules 2020,25(6),1375","journal-title":"Molecules"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/prot.26306","volume":"90","author":"Kotthoff I.","year":"2022","unstructured":"Kotthoff I.; Kundrotas P.J.; Vakser I.A.; Dockground scoring benchmarks for protein docking. Proteins 2022,90(6),1259-1266","journal-title":"Proteins"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/1568026620666201207095626","volume":"21","author":"Sulimov V.B.","year":"2021","unstructured":"Sulimov V.B.; Kutov D.C.; Taschilova A.S.; Ilin I.S.; Tyrtyshnikov E.E.; Sulimov A.V.; Docking paradigm in drug design. Curr Top Med Chem 2021,21(6),507-546","journal-title":"Curr Top Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1021\/jm00112a031","volume":"34","author":"Carini D.J.","year":"1991","unstructured":"Carini D.J.; Duncia J.V.; Aldrich P.E.; Chiu A.T.; Johnson A.L.; Pierce M.E.; Price W.A.; Santella J.B.; Wells G.J.; Wexler R.R.; Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem 1991,34(8),2525-2547","journal-title":"J Med Chem"},{"key":"ref=37","first-page":"537","volume":"7","author":"Qing S.U.","year":"2006","unstructured":"Qing S.U.; Zhou L.; Molecular design of non-peptide angiotensin II receptor blockers based on quantitative structure-activity relationship. Zhongguo Xin Yao Zazhi 2006,7,537","journal-title":"Zhongguo Xin Yao Zazhi"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/cmdc.200700082","volume":"2","author":"Lamanna C.","year":"2007","unstructured":"Lamanna C.; Catalano A.; Carocci A.; Di Mola A.; Franchini C.; Tortorella V.; Vanderheyden P.M.L.; Sinicropi M.S.; Watson K.A.; Sciabola S.; AT1 receptor ligands: Virtual-screening-based design with TOPP descriptors, synthesis, and biological evaluation of pyrrolidine derivatives. ChemMedChem 2007,2(9),1298-1310","journal-title":"ChemMedChem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00044-015-1470-1","volume":"25","author":"Smaji\u0107 M.","year":"2016","unstructured":"Smaji\u0107 M.; Nikoli\u0107 K.; Vuji\u0107 Z.; Ahmetovi\u0107 L.; Kunti\u0107 V.; 3D-QSAR studies and pharmacophore identification of AT1 receptor antagonists. Med Chem Res 2016,25(1),51-61","journal-title":"Med Chem Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e79914","DOI":"10.1371\/journal.pone.0079914","volume":"8","author":"Miura S.I.","year":"2013","unstructured":"Miura S.I.; Nakao N.; Hanzawa H.; Matsuo Y.; Saku K.; Karnik S.S.; Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. PLoS One 2013,8(11),e79914","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1021\/jm950450f","volume":"39","author":"Yanagisawa H.","year":"1996","unstructured":"Yanagisawa H.; Amemiya Y.; Kanazaki T.; Shimoji Y.; Fujimoto K.; Kitahara Y.; Sada T.; Mizuno M.; Ikeda M.; Miyamoto S.; Furukawa Y.; Koike H.; Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem 1996,39(1),323-338","journal-title":"J Med Chem"},{"key":"ref=42","author":"Zupancic S.","year":"2011","unstructured":"Zupancic S.; Pecavar A.; Vrbinc M.; Process for the preparation of olmesartan medoxomil. 2011"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1021\/op300179u","volume":"16","author":"Madasu S.B.","year":"2012","unstructured":"Madasu S.B.; Vekariya N.A.; Koteswaramma C.; Islam A.; Sanasi P.D.; Korupolu R.B.; An efficient, commercially viable, and safe process for preparation of losartan potassium, an angiotensin II receptor antagonist. Org Process Res Dev 2012,16(12),2025-2030","journal-title":"Org Process Res Dev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"10198","DOI":"10.1021\/jo202041e","volume":"76","author":"Seki M.","year":"2011","unstructured":"Seki M.; Nagahama M.; Synthesis of angiotensin II receptor blockers by means of a catalytic system for C-H activation. J Org Chem 2011,76(24),10198-10206","journal-title":"J Org Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1021\/jo00100a048","volume":"59","author":"Larsen R.D.","year":"1994","unstructured":"Larsen R.D.; King A.O.; Chen C.Y.; Corley E.G.; Foster B.S.; Roberts F.E.; Yang C.; Lieberman D.R.; Reamer R.A.; Tschaen D.M.; Verhoeven T.R.; Reider P.J.; Lo Y.S.; Rossano L.T.; Brookes A.S.; Meloni D.; Moore J.R.; Arnett J.F.; Efficient synthesis of losartan, A nonpeptide angiotensin II receptor antagonist. J Org Chem 1994,59(21),6391-6394","journal-title":"J Org Chem"},{"key":"ref=46","author":"Wu F.H.S.","year":"2011","unstructured":"Wu F.H.S.; Prepaeation method of Losartan metabolite EXP-3174. 2011"},{"key":"ref=47","author":"Ramakrishnan A.K.","year":"2011","unstructured":"Ramakrishnan A.K.; A process to manufacture pure anhydrous eprosartan mesylate. 2011"},{"key":"ref=48","author":"Gokhale N.G.C.","year":"2011","unstructured":"Gokhale N.G.C.; Process for the preparation of eprosartan. 2011"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/hr.2012.147","volume":"36","author":"Miura S.","year":"2013","unstructured":"Miura S.; Okabe A.; Matsuo Y.; Karnik S.S.; Saku K.; Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013,36(2),134-139","journal-title":"Hypertens Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biopha.2015.07.008","volume":"74","author":"Vyas V.K.","year":"2015","unstructured":"Vyas V.K.; Ghate M.; Patel K.; Qureshi G.; Shah S.; Homology modeling, binding site identification and docking study of human angiotensin II type I (Ang II-AT1) receptor. Biomed Pharmacother 2015,74,42-48","journal-title":"Biomed Pharmacother"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1021\/jm00077a007","volume":"36","author":"Ries U.J.","year":"1993","unstructured":"Ries U.J.; Mihm G.; Narr B.; Hasselbach K.M.; Wittneben H.; Entzeroth M.; van Meel J.C.A.; Wienen W.; Hauel N.H.; 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships. J Med Chem 1993,36(25),4040-4051","journal-title":"J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molstruc.2017.06.073","volume":"1147","author":"Prasad K.S.","year":"2017","unstructured":"Prasad K.S.; Nayak N.; Pillai R.R.; Armakovi\u0107 S.; Armakovi\u0107 S.J.; Novel synthetic approach, spectroscopic characterization and theoretical studies on global and local reactive properties of a bibenzimidazolyl derivative. J Mol Struct 2017,1147,121-128","journal-title":"J Mol Struct"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1021\/jm00068a011","volume":"36","author":"Kubo K.","year":"1993","unstructured":"Kubo K.; Kohara Y.; Yoshimura Y.; Inada Y.; Shibouta Y.; Furukawa Y.; Kato T.; Nishikawa K.; Naka T.; Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993,36(16),2343-2349","journal-title":"J Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1021\/op700041z","volume":"11","author":"Porcs-Makkay M.","year":"2007","unstructured":"Porcs-Makkay M.; Mezei T.; Simig G.; New practical synthesis of the key intermediate of candesartan. Org Process Res Dev 2007,11(3),490-493","journal-title":"Org Process Res Dev"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1021\/op3002867","volume":"17","author":"R\u00e1dl S.","year":"2013","unstructured":"R\u00e1dl S.; \u010cern\u00fd J.; Stach J.; Gabl\u00edkov\u00e1 Z.; Improved process for azilsartan medoxomil: A new angiotensin receptor blocker. Org Process Res Dev 2013,17(1),77-86","journal-title":"Org Process Res Dev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/0960-894X(95)00319-O","volume":"5","author":"Kohara Y.","year":"1995","unstructured":"Kohara Y.; Imamiya E.; Kubo K.; Wada T.; Inada Y.; Naka T.; A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorg Med Chem Lett 1995,5(17),1903-1908","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/me.2007-0312","volume":"22","author":"Miura S.","year":"2008","unstructured":"Miura S.; Kiya Y.; Kanazawa T.; Imaizumi S.; Fujino M.; Matsuo Y.; Karnik S.S.; Saku K.; Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008,22(1),139-146","journal-title":"Mol Endocrinol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1021\/jm00030a013","volume":"37","author":"Ellingboe J.W.","year":"1994","unstructured":"Ellingboe J.W.; Antane M.; Nguyen T.T.; Collini M.D.; Antane S.; Bender R.; Hartupee D.; White V.; McCallum J.; Park C.H.; Pyrido[2,3-d]pyrimidine angiotensin II antagonists. J Med Chem 1994,37(4),542-550","journal-title":"J Med Chem"},{"key":"ref=59","author":"Wang D.F.","year":"2010","unstructured":"Wang D.F.; Process for preparation of tasosartan. 2010"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1021\/jo701391q","volume":"72","author":"Goossen L.J.","year":"2007","unstructured":"Goossen L.J.; Melzer B.; Synthesis of valsartan via decarboxylative biaryl coupling. J Org Chem 2007,72(19),7473-7476","journal-title":"J Org Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1021\/op9000912","volume":"13","author":"Reddy B.S.","year":"2009","unstructured":"Reddy B.S.; Sinha B.K.; Mukkanti K.; Dandala R.; New and improved manufacturing process for valsartan. Org Process Res Dev 2009,13(6),1185-1189","journal-title":"Org Process Res Dev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3762\/bjoc.6.27","volume":"6","author":"Ghosh S.","year":"2010","unstructured":"Ghosh S.; Kumar A.S.; Mehta G.N.; A short and efficient synthesis of valsartan via a Negishi reaction. Beilstein J Org Chem 2010,6,27-27","journal-title":"Beilstein J Org Chem"},{"key":"ref=63","author":"Wang J.J.J.","year":"2013","unstructured":"Wang J.J.J.; Synthesis of Irbesartan. 2013"},{"key":"ref=64","author":"Bernhart C.B.","year":"1993","unstructured":"Bernhart C.B.; N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present. 1993"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1016\/j.tetlet.2012.05.145","volume":"53","author":"Estrada G.O.D.","year":"2012","unstructured":"Estrada G.O.D.; Flores M.C.; da Silva J.F.M.; de Souza R.O.M.A.; e Miranda L.S.M.; 4\u2032-Methylbiphenyl-2-carbonitrile synthesis by continuous flow Suzuki\u2013Miyaura reaction. Tetrahedron Lett 2012,53(32),4166-4168","journal-title":"Tetrahedron Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1021\/jacs.6b03215","volume":"138","author":"Chen L.","year":"2016","unstructured":"Chen L.; Ren P.; Carrow B.P.; Tri(1-adamantyl)phosphine: Expanding the boundary of electron-releasing character available to organophosphorus compounds. J Am Chem Soc 2016,138(20),6392-6395","journal-title":"J Am Chem Soc"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1055\/s-0036-1588128","volume":"28","author":"Carrow B.","year":"2017","unstructured":"Carrow B.; Chen L.; Tri(1-adamantyl)phosphine: Exceptional catalytic effects enabled by the synergy of chemical stability, donicity, and polarizability. Synlett 2017,28(3),280-288","journal-title":"Synlett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.catcom.2016.04.011","volume":"82","author":"Geng L.","year":"2016","unstructured":"Geng L.; Li Y.; Qi Z.; Fan H.; Zhou Z.; Chen R.; Wang Y.; Huang J.; Highly efficient palladium catalysts supported on nitrogen contained polymers for Suzuki-Miyaura reaction. Catal Commun 2016,82,24-28","journal-title":"Catal Commun"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cclet.2015.12.022","volume":"27","author":"Liu C.","year":"2016","unstructured":"Liu C.; Liu C.; Li X.M.; Gao Z.M.; Jin Z.L.; Oxygen-promoted Pd\/C-catalyzed Suzuki\u2013Miyaura reaction of potassium aryltrifluoroborates. Chin Chem Lett 2016,27(5),631-634","journal-title":"Chin Chem Lett"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1002\/ejoc.201700981","volume":"2017","author":"Antonacci G.","year":"2017","unstructured":"Antonacci G.; Ahlburg A.; Fristrup P.; Norrby P.O.; Madsen R.; Manganese-catalyzed cross-coupling of aryl halides and grignard reagents by a radical mechanism. Eur J Org Chem 2017,2017(32),4758-4764","journal-title":"Eur J Org Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1002\/anie.200704402","volume":"47","author":"Amatore M.","year":"2008","unstructured":"Amatore M.; Gosmini C.; Efficient cobalt-catalyzed formation of unsymmetrical biaryl compounds and its application in the synthesis of a sartan intermediate. Angew Chem Int Ed 2008,47(11),2089-2092","journal-title":"Angew Chem Int Ed"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1039\/C5GC02264A","volume":"18","author":"Rathi A.K.","year":"2016","unstructured":"Rathi A.K.; Gawande M.B.; Pechousek J.; Tucek J.; Aparicio C.; Petr M.; Tomanec O.; Krikavova R.; Travnicek Z.; Varma R.S.; Zboril R.; Maghemite decorated with ultra-small palladium nanoparticles (\u03b3-FeO\u2013Pd): applications in the Heck\u2013Mizoroki olefination, Suzuki reaction and allylic oxidation of alkenes. Green Chem 2016,18(8),2363-2373","journal-title":"Green Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1021\/jm050232e","volume":"49","author":"Ismail M.A.H.","year":"2006","unstructured":"Ismail M.A.H.; Barker S.; Abou El Ella D.A.; Abouzid K.A.M.; Toubar R.A.; Todd M.H.; Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists. J Med Chem 2006,49(5),1526-1535","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"46864","DOI":"10.1039\/C6RA03395D","volume":"6","author":"Dubey A.V.","year":"2016","unstructured":"Dubey A.V.; Kumar A.V.; A biomimetic magnetically recoverable palladium nanocatalyst for the Suzuki cross-coupling reaction. RSC Advances 2016,6(52),46864-46870","journal-title":"RSC Advances"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/ajoc.201700137","volume":"6","author":"Patel N.D.","year":"2017","unstructured":"Patel N.D.; Rivalti D.; Buono F.G.; Chatterjee A.; Qu B.; Braith S.; Desrosiers J.N.; Rodriguez S.; Sieber J.D.; Haddad N.; Fandrick K.R.; Lee H.; Yee N.K.; Busacca C.A.; Senanayake C.H.; Effective BI-DIME ligand for suzuki-miyaura cross-coupling reactions in water with 500 ppm palladium loading and triton X. Asian J Org Chem 2017,6(9),1285-1291","journal-title":"Asian J Org Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1002\/ejoc.201500353","volume":"2015","author":"Nallasivam J.L.","year":"2015","unstructured":"Nallasivam J.L.; Fernandes R.A.; Development of Unimolecular Tetrakis(piperidin-4-ol) as a Ligand for suzuki-miyaura cross-coupling reactions: Synthesis of incrustoporin and preclamol. Eur J Org Chem 2015,2015(16),3558-3567","journal-title":"Eur J Org Chem"},{"key":"ref=77","author":"Chakravarty P.K.G.","year":"1992","unstructured":"Chakravarty P.K.G.; Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists. 1992"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejmech.2012.07.040","volume":"55","author":"Agelis G.","year":"2012","unstructured":"Agelis G.; Resvani A.; Durdagi S.; Spyridaki K.; T\u016fmov\u00e1 T.; Slaninov\u00e1 J.; Giannopoulos P.; Vlahakos D.; Liapakis G.; Mavromoustakos T.; Matsoukas J.; The discovery of new potent non-peptide angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem 2012,55,358-374","journal-title":"Eur J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3998\/ark.5550190.0009.229","volume":"2008","author":"Rapposelli S.","year":"2008","unstructured":"Rapposelli S.; Cuboni S.; Digiacomo M.; Lapucci A.; Trincavelli M.L.; Tuccinardi T.; Balsamo A.; Synthesis and AT1 affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton. ARKIVOC 2008,2008(2),268-286","journal-title":"ARKIVOC"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0960-894X(03)00251-8","volume":"13","author":"Moutevelis-Minakakis P.","year":"2003","unstructured":"Moutevelis-Minakakis P.; Gianni M.; Stougiannou H.; Zoumpoulakis P.; Zoga A.; Vlahakos A.D.; Iliodromitis E.; Mavromoustakos T.; Design and synthesis of novel antihypertensive drugs. Bioorg Med Chem Lett 2003,13(10),1737-1740","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2009.07.022","volume":"311","author":"Vauquelin G.","year":"2009","unstructured":"Vauquelin G.; Packeu A.; Ligands, their receptors and \u2026 plasma membranes. Mol Cell Endocrinol 2009,311(1-2),1-10","journal-title":"Mol Cell Endocrinol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"183142","DOI":"10.1016\/j.bbamem.2019.183142","volume":"1862","author":"Kiriakidi S.","year":"2022","unstructured":"Kiriakidi S.; Chatzigiannis C.; Papaemmanouil C.; Tzakos A. G.; Mavromoustakos T.; Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor. Biochim Biophys Acta Biomembr 2022,1862(3),183142","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/molecules26010012","volume":"26","author":"Chontzopoulou E.","year":"2020","unstructured":"Chontzopoulou E.; Tzakos A.G.; Mavromoustakos T.; On the rational drug design for hypertension through NMR spectroscopy. Molecules 2020,26(1),12","journal-title":"Molecules"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.bbamem.2013.12.012","volume":"1838","author":"Zervou M.","year":"2014","unstructured":"Zervou M.; Cournia Z.; Potamitis C.; Patargias G.; Durdagi S.; Grdadolnik S.G.; Mavromoustakos T.; Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach. Biochim Biophys Acta Biomembr 2014,1838(3),1031-1046","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3390\/v14051029","volume":"14","author":"Ridgway H.","year":"2022","unstructured":"Ridgway H.; Chasapis C.T.; Kelaidonis K.; Ligielli I.; Moore G.J.; Gadanec L.K.; Zulli A.; Apostolopoulos V.; Mavromoustakos T.; Matsoukas J.M.; Understanding the driving forces that trigger mutations in SARS-CoV-2: Mutational energetics and the role of arginine blockers in COVID-19 therapy. Viruses 2022,14(5),1029","journal-title":"Viruses"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220829101436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208118\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220829101436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:24:21Z","timestamp":1693671861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208118\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":85,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220829101436","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}